Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, CA.
Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA.
Pediatr Crit Care Med. 2020 Mar;21(3):256-266. doi: 10.1097/PCC.0000000000002127.
To describe the epidemiology, critical care interventions, and mortality of children with pulmonary hypertension receiving extracorporeal membrane oxygenation.
Retrospective analysis of prospectively collected multicenter data.
Data entered into the Extracorporeal Life Support Organization database between January 2007 and November 2018.
Pediatric patients between 28 days and 18 years old with a diagnosis of pulmonary hypertension.
Six hundred thirty-four extracorporeal membrane oxygenation runs were identified (605 patients). Extracorporeal membrane oxygenation support type was pulmonary (43.1%), cardiac (40.2%), and extracorporeal cardiopulmonary resuscitation (16.7%). The majority of cannulations were venoarterial (80.4%), and 30% had a pre-extracorporeal membrane oxygenation cardiac arrest. Mortality in patients with pulmonary hypertension was 51.3% compared with 44.8% (p = 0.001) in those without pulmonary hypertension. In univariate analyses, significant predictors of mortality included age less than 6 months and greater than 5 years; pre-extracorporeal membrane oxygenation cardiac arrest; pre-extracorporeal membrane oxygenation blood gas with pH less than 7.12, PaCO2 greater than 75, PaO2 less than 35, and arterial oxygen saturation less than 60%; extracorporeal membrane oxygenation duration greater than 280 hours; extracorporeal cardiopulmonary resuscitation; and extracorporeal membrane oxygenation complications including cardiopulmonary resuscitation, inotropic support, myocardial stun, tamponade, pulmonary hemorrhage, intracranial hemorrhage, seizures, other hemorrhage, disseminated intravascular coagulation, renal replacement therapy, mechanical/circuit problem, and metabolic acidosis. A co-diagnosis of pneumonia was associated with significantly lower odds of mortality (odds ratio, 0.5; 95% CI, 0.3-0.8). Prediction models were developed using three sets of variables: 1) pre-extracorporeal membrane oxygenation (age, absence of pneumonia, and pH < 7.12; area under the curve, 0.62); 2) extracorporeal membrane oxygenation related (extracorporeal cardiopulmonary resuscitation, any neurologic complication, pulmonary hemorrhage, renal replacement therapy, and metabolic acidosis; area under the curve, 0.72); and 3) all variables combined (area under the curve, 0.75) (p < 0.001).
Children with pulmonary hypertension who require extracorporeal membrane oxygenation support have a significantly greater odds of mortality compared with those without pulmonary hypertension. Risk factors for mortality include age, absence of pneumonia, pre-extracorporeal membrane oxygenation acidosis, extracorporeal cardiopulmonary resuscitation, pulmonary hemorrhage, neurologic complications, renal replacement therapy, and acidosis while on extracorporeal membrane oxygenation. Identification of those pulmonary hypertension patients requiring extracorporeal membrane oxygenation who are at even higher risk for mortality may inform clinical decision-making and improve prognostic awareness.
描述接受体外膜氧合的肺动脉高压儿童的流行病学、重症监护干预措施和死亡率。
前瞻性收集的多中心数据的回顾性分析。
2007 年 1 月至 2018 年 11 月期间在体外生命支持组织数据库中输入的数据。
年龄在 28 天至 18 岁之间、诊断为肺动脉高压的儿科患者。
共确定了 634 例体外膜氧合运行(605 例患者)。体外膜氧合支持类型为肺(43.1%)、心脏(40.2%)和体外心肺复苏(16.7%)。大多数插管为静脉动脉(80.4%),30%的患者在体外膜氧合前有心脏骤停。与无肺动脉高压患者(44.8%)相比,肺动脉高压患者的死亡率为 51.3%(p=0.001)。在单变量分析中,死亡率的显著预测因素包括年龄小于 6 个月和大于 5 岁;体外膜氧合前心脏骤停;体外膜氧合前血气 pH 值小于 7.12、PaCO2 大于 75、PaO2 小于 35 和动脉血氧饱和度小于 60%;体外膜氧合持续时间大于 280 小时;体外心肺复苏;体外膜氧合并发症包括心肺复苏、正性肌力支持、心肌顿抑、心脏压塞、肺出血、颅内出血、癫痫发作、其他出血、弥漫性血管内凝血、肾脏替代治疗、机械/回路问题和代谢性酸中毒。肺炎的合并诊断与死亡率显著降低相关(比值比,0.5;95%置信区间,0.3-0.8)。使用三组变量开发了预测模型:1)体外膜氧合前(年龄、无肺炎和 pH 值<7.12;曲线下面积,0.62);2)体外膜氧合相关(体外心肺复苏、任何神经并发症、肺出血、肾脏替代治疗和代谢性酸中毒;曲线下面积,0.72);和 3)所有变量组合(曲线下面积,0.75)(p<0.001)。
需要体外膜氧合支持的肺动脉高压儿童的死亡率明显高于无肺动脉高压的儿童。死亡率的危险因素包括年龄、无肺炎、体外膜氧合前酸中毒、体外心肺复苏、肺出血、神经并发症、肾脏替代治疗和体外膜氧合时酸中毒。识别那些肺动脉高压患者需要体外膜氧合,并且死亡率风险更高,可能会为临床决策提供信息,并提高预后意识。